HR Execs on the Move

Rénibus Therapeutics

www.renibus.com

 
Rénibus Therapeutics® Inc. | A biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.renibus.com
  • 181, Grand Avenue
    Southlake, TX USA 76092
  • Phone: 682.285.1711

Executives

Name Title Contact Details
Jamie Donadio
Chief Financial Officer Profile

Similar Companies

Sertech

Sertech is a Batavia, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

HNP Pharmaceuticals

HNP Pharmaceuticals is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bracco Diagnostics

Established in August 1994, Bracco Diagnostics Inc. develops and markets a wide range of diagnostic imaging agents in the U.S. Bracco products are currently used in conjunction with X-ray, CT, MRI, and nuclear medicine. Bracco Diagnostics Inc. is a

DPT Laboratories

DPT is a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms. Recognized globally for technical expertise and virtually unlimited manufacturing capabilities, DPT is the industry source for fully

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.